Assessment of Serum Uric Acid in Young Male Patients with Ankylosing Spondylitis

To the Editor:
We read with great interest the article entitled "Low levels of serum uric acid increase the risk of low bone mineral density in young male patients with ankylosing spondylitis 1 ". Thanks to Kang and colleagues for their valuable investigation in which they concluded that lower serum uric acid (SUA) levels were associated with lower bone mineral density in young male patients with ankylosing spondylitis and that SUA might be a predictive biomarker or therapeutic target in these patients. However, we think that some issues have to be emphasized when assessing SUA levels.
Generating the study population is perhaps the most important step of a research study. In this respect, exclusion criteria carry a big importance. In their study, the authors defined several exclusion criteria that we consider insufficient. Several researchers have suggested that these diseases can affect SUA concentrations: metabolic syndrome, systemic inflammation, cardiovascular diseases, diabetes mellitus, nonalcoholic fatty liver disease, peripheral arterial disease, hypertension, multiple sclerosis, dyslipidemia, and Parkinson disease 2, 3 . In addition to these disorders, several kinds of drugs were suggested to alter SUA levels, such as hypoglycemic agents (e.g., metformin), weight-reducing drugs (e.g., orlistat), lipid-lowering drugs (e.g., fenofibrate, simvastatin, ezetimibe, atorvastatin), calcium channel blockers (e.g., amlodipine), angiotensin-converting enzyme inhibitors (e.g., captopril, enalapril, ramipril), angiotensin II receptor antagonists (e.g., losartan), estrogens, corticosteroids, and the dietary food supplements vitamin C, vitamin A, iron, flavonoids, omega 3 fatty acids, zinc, and β-carotene 4, 5 .
